ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
-1%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$128M
AUM Growth
+$128M
(-21%)
Cap. Flow
-$25.8M
Cap. Flow
% of AUM
-20.08%
Top 10 Holdings %
Top 10 Hldgs %
71.04%
Holding
41
New
5
Increased
6
Reduced
13
Closed
6
Top Buys
| 1 |
Apellis Pharmaceuticals
APLS
|
$4.82M |
| 2 |
4D Molecular Therapeutics
FDMT
|
$1.8M |
| 3 |
argenx
ARGX
|
$1.67M |
| 4 |
Alkermes
ALKS
|
$893K |
| 5 |
Kura Oncology
KURA
|
$780K |
Top Sells
| 1 |
Viridian Therapeutics
VRDN
|
$5.81M |
| 2 |
Sarepta Therapeutics
SRPT
|
$4.79M |
| 3 |
BioAtla
BCAB
|
$4.13M |
| 4 |
Mersana Therapeutics
MRSN
|
$3.66M |
| 5 |
Keros Therapeutics
KROS
|
$3.26M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $19.2M | 14.12% | 290,500 +73,000 | +34% | +$4.82M |
|
|
WHWK
2
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.1M
| $13.4M | 9.86% | 1,849,402 | – | – |
|
3
Terns Pharmaceuticals
TERN
$609M
| $13M | 9.59% | 1,099,309 -691 | -0.1% | -$8.18K |
|
|
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
| $7.66M | 5.64% | 878,500 -136,500 | -13% | -$1.19M |
|
5
Ventyx Biosciences
VTYX
$171M
| $6.98M | 5.15% | 208,500 -82,000 | -28% | -$2.75M |
|
6
Syndax Pharmaceuticals
SNDX
$1.41B
| $6.97M | 5.13% | 330,000 +5,386 | +2% | +$114K |
|
|
7
Kura Oncology
KURA
$686M
| $6.91M | 5.09% | 565,257 +63,757 | +13% | +$780K |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $6.82M | 5.03% | 280,500 -80,000 | -22% | -$1.95M |
|
9
United Therapeutics
UTHR
$13.8B
| $5.26M | 3.88% | 23,500 -9,500 | -29% | -$2.13M |
|
10
Rocket Pharmaceuticals
RCKT
$354M
| $5.1M | 3.76% | 298,000 +38,000 | +15% | +$651K |
|
|
BLU
11
DELISTED
BELLUS Health Inc.
BLU
| $4.55M | 3.35% | 632,500 | – | – |
|
|
12
Sarepta Therapeutics
SRPT
$1.78B
| $4.52M | 3.33% | 32,770 -34,730 | -51% | -$4.79M |
|
13
Vaxcyte
PCVX
$4B
| $4.52M | 3.33% | 120,500 -24,000 | -17% | -$900K |
|
14
Celldex Therapeutics
CLDX
$1.47B
| $4.37M | 3.22% | 121,500 +6,500 | +6% | +$234K |
|
|
15
Viridian Therapeutics
VRDN
$1.5B
| $4.27M | 3.15% | 168,000 -228,500 | -58% | -$5.81M |
|
|
16
argenx
ARGX
$43.6B
| $3.57M | 2.63% | 9,594 +4,494 | +88% | +$1.67M |
|
17
GH Research
GHRS
$837M
| $1.94M | 1.43% | 243,250 | – | – |
|
|
18
4D Molecular Therapeutics
FDMT
$288M
| $1.8M | 1.33% | +104,753 | New | +$1.8M |
|
19
Aclaris Therapeutics
ACRS
$209M
| $986K | 0.73% | 121,840 -133,160 | -52% | -$1.08M |
|
20
Iovance Biotherapeutics
IOVA
$807M
| $939K | 0.69% | 153,639 | – | – |
|
|
21
Alkermes
ALKS
$4.78B
| $893K | 0.66% | +31,689 | New | +$893K |
|
22
EyePoint Pharmaceuticals
EYPT
$797M
| $892K | 0.66% | 303,396 | – | – |
|
23
PMV Pharmaceuticals
PMVP
$74.2M
| $737K | 0.54% | 154,471 | – | – |
|
24
Rezolute
RZLT
$619M
| $703K | 0.52% | 366,204 -53,796 | -13% | -$103K |
|
25
Enliven Therapeutics
ELVN
$1.2B
| $678K | 0.5% | 30,979 -13,524 | -30% | -$296K |
|